© 1999 by European Society of Cardiology
Copyright © 1999, European Society of Cardiology
Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis
Experimental Physiology and Pharmacology Section, Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
* Corresponding author. Present address: The Johns Hopkins University School of Medicine, Division of Cardiology, A1 East, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD 21224, USA. Tel.: +1-410-550-7035; fax: +1-410-550-1183 dlazarou{at}welch.jhu.edu
Objective: Angiogenic peptides like VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor) have entered clinical trials for coronary artery disease. Attempts are being made to devise clinically relevant means of delivery and to effect site-specific delivery of these peptides to the cardiac tissue, in order to limit systemic side-effects. We characterized the response of the pericardium to delivery of a replication-deficient adenovirus carrying the cDNA for AdCMV.VEGF165, and assessed the effect of pericardial VEGF165 on myocardial collateral development in a canine model of progressive coronary occlusion. Methods: Ameroid constrictors were placed on the proximal left circumflex coronary artery of mongrel dogs. Ten days later, 6x109 pfu AdCMV.VEGF165 (n=9), AdRSV.β-gal (n=9), or saline (n=7) were injected through an indwelling pericardial catheter. Transfection efficiency was assessed by X-gal staining. Pericardial and serum VEGF levels were measured serially by ELISA. Maximal myocardial collateral perfusion was quantified with radiolabeled or fluorescent microspheres 28 days after treatment. Results: In AdRSV.β-gal-treated dogs, there was extensive β-gal staining in the pericardium and epicardium, with minimal β-gal staining in the mid-myocardium and endocardium. Pericardial delivery of AdCMV.VEGF165 resulted in sustained (8–14 day) pericardial transgene expression, with VEGF levels peaking 3 days after infection (>200 ng/ml) and decreasing thereafter. There was no detectable increase in serum VEGF levels. Maximal collateral perfusion, a principal correlate of collateral development and angiogenesis, was equivalent in all groups. Conclusion: Adenoviral-mediated gene transfer is capable of inducing sustained VEGF165 expression in the pericardium; however, locally targeted pericardial VEGF delivery failed to improve myocardial collateral perfusion in this model.
KEYWORDS Collateral circulation; Coronary circulation; Gene therapy; Growth factors; Ischemia
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Seko, N. Nitta, A. Sonoda, S. Ohta, M. Takahashi, K. Murata, and Y. Tabata Vascular Regeneration by Repeated Infusions of Basic Fibroblast Growth Factor in a Rabbit Model of Hind-Limb Ischemia Am. J. Roentgenol., June 1, 2009; 192(6): W306 - W310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Szabo, J. Laki, H. O. Madsen, E. Dosa, Z. Prohaszka, S. Rugonfalvi-Kiss, M. Kokai, G. Acsadi, I. Karadi, L. Entz, et al. Early Rise in Serum VEGF and PDGF Levels Predisposes Patients With a Normal MBL2 Genotype to Restenosis After Eversion Endarterectomy Stroke, August 1, 2007; 38(8): 2247 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Markkanen, T. T. Rissanen, A. Kivela, and S. Yla-Herttuala Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy Cardiovasc Res, February 15, 2005; 65(3): 656 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ye, H. K Haider, S.-J. Jiang, and E. K. Sim Therapeutic Angiogenesis Using Vascular Endothelial Growth Factor Asian Cardiovasc Thorac Ann, June 1, 2004; 12(2): 173 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Lambert, R. Michel, G.-M. Mazmanian, E. M. Dulmet, A. Capderou, P. Herve, C. Planche, and A. Serraf Induction of pulmonary angiogenesis by adenoviral-mediated gene transfer of vascular endothelial growth factor Ann. Thorac. Surg., February 1, 2004; 77(2): 458 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hiraoka, H. Koike, S. Yamamoto, N. Tomita, C. Yokoyama, T. Tanabe, T. Aikou, T. Ogihara, Y. Kaneda, and R. Morishita Enhanced Therapeutic Angiogenesis by Cotransfection of Prostacyclin Synthase Gene or Optimization of Intramuscular Injection of Naked Plasmid DNA Circulation, November 25, 2003; 108(21): 2689 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Giordano Retrograde coronary perfusion: a superior route to deliver therapeutics to the heart? J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1129 - 1131. [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Mohammed, B. A. Craig, A. J. Mutsaers, N. W. Glickman, P. W. Snyder, A. E. deGortari, D. L. Schlittler, K. T. Coffman, P. L. Bonney, and D. W. Knapp Effects of the Cyclooxygenase Inhibitor, Piroxicam, in Combination with Chemotherapy on Tumor Response, Apoptosis, and Angiogenesis in a Canine Model of Human Invasive Urinary Bladder Cancer Mol. Cancer Ther., February 1, 2003; 2(2): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruel, R. A. Kelly, and F. W. Sellke Therapeutic Angiogenesis, Transmyocardial Laser Revascularization, and Cell Therapy Card. Surg. Adult, January 1, 2003; 2(2003): 715 - 750. [Full Text]
|
|
|
|
 |
|
 J. J. R. Hermans, H. van Essen, H. A. J. Struijker-Boudier, R. M. Johnson, F. Theeuwes, and J. F. M. Smits Pharmacokinetic Advantage of Intrapericardially Applied Substances in the Rat J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 672 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Mohammed, P. F. Bennett, B. A. Craig, N. W. Glickman, A. J. Mutsaers, P. W. Snyder, W. R. Widmer, A. E. DeGortari, P. L. Bonney, and D. W. Knapp Effects of the Cyclooxygenase Inhibitor, Piroxicam, on Tumor Response, Apoptosis, and Angiogenesis in a Canine Model of Human Invasive Urinary Bladder Cancer Cancer Res., January 1, 2002; 62(2): 356 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Freedman and J. M. Isner Therapeutic Angiogenesis for Coronary Artery Disease Ann Intern Med, January 1, 2002; 136(1): 54 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Lindner and T. Maciag The Putative Convergent and Divergent Natures of Angiogenesis and Arteriogenesis Circ. Res., October 26, 2001; 89(9): 747 - 749. [Full Text] [PDF]
|
|
|
|
|
|
E. F Unger Experimental evaluation of coronary collateral development Cardiovasc Res, February 16, 2001; 49(3): 497 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.K. Hammond and M.D. McKirnan Angiogenic gene therapy for heart disease: a review of animal studies and clinical trials Cardiovasc Res, February 16, 2001; 49(3): 561 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Amann and E. Ritz Microvascular disease--the Cinderella of uraemic heart disease Nephrol. Dial. Transplant., October 1, 2000; 15(10): 1493 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Su, R. Lu, and Y. W. Kan Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart PNAS, December 5, 2000; 97(25): 13801 - 13806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Deindl, I. Buschmann, I. E. Hoefer, T. Podzuweit, K. Boengler, S. Vogel, N. van Royen, B. Fernandez, and W. Schaper Role of Ischemia and of Hypoxia-Inducible Genes in Arteriogenesis After Femoral Artery Occlusion in the Rabbit Circ. Res., October 26, 2001; 89(9): 779 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics, December 21, 2001; 7(2): 79 - 94. [Abstract] [Full Text] [PDF]
|
|